Carl Zeiss Meditec AG (AFX.DE)
| Previous Close | 102.60 |
| Open | 102.90 |
| Bid | 100.60 x 18700 |
| Ask | 101.10 x 15000 |
| Day's Range | 100.20 - 103.00 |
| 52 Week Range | 72.60 - 124.35 |
| Volume | |
| Avg. Volume | 133,225 |
| Market Cap | 8.98B |
| Beta (5Y Monthly) | 0.90 |
| PE Ratio (TTM) | 32.39 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.10 (1.07%) |
| Ex-Dividend Date | Mar 22, 2024 |
| 1y Target Est | N/A |
- PR Newswire
Carl Zeiss Meditec AG Completes Acquisition of Dutch Ophthalmic Research Center (D.O.R.C.); Companies Unite to Shape Ophthalmology Market
Carl Zeiss Meditec AG announced today that, after securing all required regulatory approvals, it has completed the acquisition of 100% of D.O.R.C. (Dutch Ophthalmic Research Center) from the investment firm Eurazeo SE, Paris, France. The acquisition enhances and complements ZEISS Medical Technology's broad ophthalmic portfolio and range of digitally connected workflow solutions for addressing a wide variety of eye conditions, spanning retina and cornea disorders, cataract, glaucoma, and refracti
- CNW Group
ZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024
ZEISS Medical Technology will showcase the latest in 3D visualization technology and surgical innovation at the American Society of Cataract and Refractive Surgery (ASCRS) conference from April 5-8, 2024, in Boston, MA. Building on its ZEISS Medical Ecosystem, several of the new innovations enable seamless data integration and management across the cataract and refractive workflows, creating a new standard for efficient, personalized ophthalmic care.
- CNW Group
U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS
Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The latest generation of femtosecond lasers from ZEISS enters the U.S. market at a time when more than 8 million eyes have been treated with SMILE worldwide, reflecting the technology's broad global momentum driven by strong adoption in Asia and Eur
